@article{5fd3840077a911df9abd000ea68e967b,
title = "Translation of randomised controlled trial findings into clinical practice: comparison of olanzapine and valproate in the EMBLEM study",
abstract = "OBJECTIVES: The aim of this study was to compare the outcomes of olanzapine- and valproate-treated patients in an observational study of acute mania with the results of a randomised controlled trial (RCT) assessing the same treatments. METHODS: EMBLEM (European Mania in Bipolar Evaluation of Medication) was a 2-year, prospective, observational study of health outcomes associated with the treatment of mania. Severity of mania and depression were assessed at baseline and 6 weeks using the YMRS and the 5-item version of the HAMD, respectively. RESULTS: 621 patients were analysed (n=107 valproate, n=514 olanzapine). Both groups improved from baseline to 6 weeks in mean YMRS and HAMD-5 total scores, with greater mean improvements in the olanzapine compared with the valproate group. Olanzapine was associated with more weight gain and less gastrointestinal difficulties than valproate. DISCUSSION: The EMBLEM results support those of the RCT, which suggest that olanzapine monotherapy seems to be more effective than valproate monotherapy in the treatment of acute mania.",
author = "D Novick and A Gonzalez-Pinto and Haro, {J M} and J Bertsch and C Reed and E Perrin and M Tohen and larsen, {jens knud} and Larsen, {Jens Knud}",
note = "Keywords: Adult; Antidepressive Agents; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Female; Gastrointestinal Diseases; Humans; Male; Prospective Studies; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Treatment Outcome; Valproic Acid; Weight Gain",
year = "2009",
doi = "10.1055/s-0028-1128115",
language = "English",
volume = "42",
pages = "145--52",
journal = "Pharmacopsychiatry",
issn = "0176-3679",
publisher = "Georg/Thieme Verlag",
number = "4",
}